US EditionPublished • loading... • Updated
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
Longer plans cut monthly costs and can save self-pay patients up to $1,200 a year on the injection and $600 on the pill, Novo said.
- Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly prices up to nearly 30% below its standard rate.
- The new programme, available through telehealth platforms, lets eligible self-pay patients buy three-, six- or 12-month supplies at fixed monthly prices, with longer plans offering bigger reductions.
- Novo is increasingly leaning on telehealth and direct distribution to reach patients paying out of pocket, a shift outside of traditional insurance channels and doctors' offices.
Insights by Ground AI
26 Articles
26 Articles
Coverage Details
Total News Sources26
Leaning Left9Leaning Right1Center10Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 45%
C 50%
Factuality
To view factuality data please Upgrade to Premium
